ARS Pharmaceuticals, Inc. (SPRY)
3.655
0.00 (0.00%)
USD |
NASDAQ |
Oct 29, 16:00
3.655
0.00 (0.00%)
After-Hours: 19:58
ARS Pharmaceuticals Enterprise Value : 315.78M for Oct. 28, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 28, 2026 | 315.78M |
| October 27, 2026 | 323.73M |
| October 26, 2026 | 342.63M |
| October 23, 2026 | 353.57M |
| October 22, 2026 | 382.40M |
| October 21, 2026 | 368.48M |
| October 20, 2026 | 379.42M |
| October 19, 2026 | 373.45M |
| October 16, 2026 | 352.57M |
| October 15, 2026 | 357.54M |
| October 14, 2026 | 343.62M |
| October 13, 2026 | 355.55M |
| October 12, 2026 | 368.48M |
| October 09, 2026 | 373.45M |
| October 08, 2026 | 406.27M |
| October 07, 2026 | 386.38M |
| October 06, 2026 | 379.92M |
| October 05, 2026 | 379.42M |
| October 02, 2026 | 357.54M |
| October 01, 2026 | 362.52M |
| September 30, 2026 | 381.41M |
| September 29, 2026 | 390.36M |
| September 28, 2026 | 363.51M |
| September 25, 2026 | 358.54M |
| September 24, 2026 | 365.50M |
| Date | Value |
|---|---|
| September 23, 2026 | 368.48M |
| September 22, 2026 | 398.31M |
| September 21, 2026 | 385.39M |
| September 18, 2026 | 361.52M |
| September 17, 2026 | 365.50M |
| September 16, 2026 | 366.99M |
| September 15, 2026 | 375.44M |
| September 14, 2026 | 400.30M |
| September 11, 2026 | 426.16M |
| September 10, 2026 | 455.99M |
| September 09, 2026 | 472.89M |
| September 08, 2026 | 488.80M |
| September 04, 2026 | 511.67M |
| September 03, 2026 | 516.64M |
| September 02, 2026 | 531.56M |
| September 01, 2026 | 526.59M |
| August 31, 2026 | 549.46M |
| August 28, 2026 | 538.52M |
| August 27, 2026 | 552.44M |
| August 26, 2026 | 552.44M |
| August 25, 2026 | 521.62M |
| August 24, 2026 | 484.82M |
| August 21, 2026 | 500.24M |
| August 20, 2026 | 500.24M |
| August 19, 2026 | 587.24M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Capricor Therapeutics, Inc. | 215.13M |
| Sionna Therapeutics, Inc. | -20.50M |
| Nektar Therapeutics | 767.29M |
| Ardelyx, Inc. | 746.72M |
| Kyntra Bio, Inc. | -50.21M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -62.34M |
| Revenue (Quarterly) | 33.66M |
| Total Expenses (Quarterly) | 96.00M |
| EPS Diluted (Quarterly) | -0.6277 |
| Gross Profit Margin (Quarterly) | 61.83% |
| Profit Margin (Quarterly) | -185.2% |
| Earnings Yield | -59.46% |
| Normalized Earnings Yield | -59.47 |